Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 2
1995 2
1996 9
1997 4
1998 3
1999 2
2000 3
2001 1
2002 3
2003 4
2004 3
2005 3
2006 3
2007 3
2008 4
2009 3
2010 6
2011 5
2012 5
2013 7
2014 5
2015 9
2016 6
2017 8
2018 10
2019 8
2020 16
2021 16
2022 17
2023 11
2024 12
2025 11
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

185 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.
Parmar G, Capra M, Seguro F, Hungria V, Dimopoulos MA, Delimpasi S, Minařík J, Špička I, Pour L, Marques H, Esteves G, Sunami K, Yuda J, Hájek R, Mihályová J, Soufflet C, Yu D, Benlhassan K, Koch V, Comerford E, Cordero P, Suzan F, Quach H. Parmar G, et al. Among authors: spicka i. Blood Cancer J. 2025 Dec 27;16(1):16. doi: 10.1038/s41408-025-01436-0. Blood Cancer J. 2025. PMID: 41455697 Free PMC article. Clinical Trial.
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.
Jungova A, Stork M, Spicka I, Radocha J, Minarik J, Pavlicek P, Mihalyova J, Pour L, Straub J, Maisnar V, Pika T, Dekojova T, Soukup J, Popkova T, Mensikova K, Sedlák F, Pospiskova J, Boichuk I, Krhovska P, Stopka T, Jindra P, Jelínek T, Knechtová Z, Capounova V, Latal V, Muronova L, Heindorfer A, Ullrychova J, Sykora M, Kessler P, Hajek R. Jungova A, et al. Among authors: spicka i. Clin Lymphoma Myeloma Leuk. 2025 Nov 2:S2152-2650(25)04269-7. doi: 10.1016/j.clml.2025.10.022. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2025. PMID: 41339214
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S; DREAMM-8 investigators. Dimopoulos MA, et al. Among authors: spicka i. Lancet Haematol. 2025 Nov;12(11):e876-e886. doi: 10.1016/S2352-3026(25)00256-X. Lancet Haematol. 2025. PMID: 41193117 Clinical Trial.
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.
Stork M, Radocha J, Mihalyova J, Spicka I, Pika T, Jungova A, Boichuk I, Mensikova K, Straub J, Sedlak F, Minarik J, Krhovska P, Novakova D, Hornakova M, Knechtova Z, Sendlerova N, Dekojova T, Maisnar V, Jelinek T, Hajek R, Pour L. Stork M, et al. Among authors: spicka i. Ann Hematol. 2025 Aug;104(8):4141-4147. doi: 10.1007/s00277-025-06529-1. Epub 2025 Aug 18. Ann Hematol. 2025. PMID: 40824489 Free PMC article.
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J, Goldschmidt H, Zhang R, Sémiond D, Suzan F, Stefanova-Urena M, Koch V, Moreau P. Ailawadhi S, et al. Among authors: spicka i. J Clin Oncol. 2025 Sep 20;43(27):3056. doi: 10.1200/JCO-25-01767. Epub 2025 Aug 8. J Clin Oncol. 2025. PMID: 40779730 No abstract available.
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelínek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Mateos MV, et al. Among authors: spicka i. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949. Blood Adv. 2025. PMID: 40763276 Free PMC article. Clinical Trial.
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.
Paul B, Minarik J, Cottini F, Gasparetto C, Khouri J, Gandhi M, Hillengass J, Levy M, Liedtke M, Manda S, Sandhu I, Sborov D, Spicka I, Usmani S, Dong M, Gu L, Leung C, Doshi P, Chen C, Pour L. Paul B, et al. Among authors: spicka i. EJHaem. 2025 Jun 6;6(3):e70072. doi: 10.1002/jha2.70072. eCollection 2025 Jun. EJHaem. 2025. PMID: 40485906 Free PMC article.
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J, Goldschmidt H, Zhang R, Sémiond D, Suzan F, Stefanova-Urena M, Koch V, Moreau P. Ailawadhi S, et al. Among authors: spicka i. J Clin Oncol. 2025 Aug;43(22):2527-2537. doi: 10.1200/JCO-25-00744. Epub 2025 Jun 3. J Clin Oncol. 2025. PMID: 40459178 Clinical Trial.
A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.
Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Anderson KC. Richardson PG, et al. Among authors: spicka i. Future Oncol. 2025 Mar;21(6):653-663. doi: 10.1080/14796694.2025.2449781. Epub 2025 Jan 24. Future Oncol. 2025. PMID: 39851267 Free PMC article.
185 results